Effects of Perinatal Nicotine Exposure on Development of [3H]Hemicholinium-3 Binding Sites in Rat Neonate Brain.

DOI Web Site Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 参考文献30件
  • Zhu Jun
    Department of Pharmacology,School of Medicine,Fukui Medical University,Matsuoka,Fukui 910-1193,Japan
  • Taniguchi Takanobu
    Department of Pharmacology,School of Medicine,Fukui Medical University,Matsuoka,Fukui 910-1193,Japan
  • Tanaka Takashi
    Department of Pharmacology,School of Medicine,Fukui Medical University,Matsuoka,Fukui 910-1193,Japan
  • Suzuki Fumiko
    Department of Pharmacology,School of Medicine,Fukui Medical University,Matsuoka,Fukui 910-1193,Japan
  • Muramatsu Ikunobu
    Department of Pharmacology,School of Medicine,Fukui Medical University,Matsuoka,Fukui 910-1193,Japan

この論文をさがす

抄録

In this study, [3H]hemicholinium−3([3H]HC−3)binding, which labels the presynaptic high affinity−choline transport sites, was examined in two brain regions, cerebral cortex and midbrain, of nicotine−treated and −untreated rat neonates.In nicotine−untreated neonates, [3H]HC−3 binding sites of cerebral cortex increased from 64 fmol/mg protein at postnatal day 7 to 142 fmol/mg protein at postnatal day 35.In nicotine−treated neonates, the development of [3H]HC−3 binding sites in cerebral cortex was significantly retarded, compared with control neonates on the 7th, 14th and 21st postnatal days.In parallel with this, the development of muscarinic receptor in cerebral cortex, which was detected by [3H]quinuclidinyl benzylate([3H]QNB)binding, was also retarded by nicotine treatment.However, in midbrain, neither [3H]HC−3 nor [3H]QNB binding sites at postnatal day 14 was affected by nicotine treatment.These results strongly suggest that perinatal treatment with nicotine inhibits presynaptic and postsynaptic development of the cholinergic pathway in cerebral cortex but not in midbrain of rat neonate.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 84 (1), 32-35, 2000

    公益社団法人 日本薬理学会

参考文献 (30)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ